^
12d
A NASBi-Cas13a E-Sensor for Accurate Diagnosis of Acute Promyelocytic Leukemia: RNA and DNA Cotargeting LbuCas13a by Cell-Free Transcription Amplification. (PubMed, Anal Chem)
Furthermore, in five cases, this method accurately monitored changes in transcript levels. This method, due to its simplified process without reverse transcription and thermal cycling as well as the free of clumsy instrument, holds promise as a point-of-care tool for MRD detection and could potentially prove invaluable in the regular follow-up and efficacy evaluation of cancer treatment.
Journal
|
RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
14d
Upregulation of GnT-IVa and Its Critical Roles in ATRA-Induced Differentiation of Acute Promyelocytic Leukemia Cells. (PubMed, Biomolecules)
In addition, MGAT4A KO suppressed ERK/MAPK signaling, which contributed to differentiation. Our study highlights the critical role of GnT-IVa in regulating APL differentiation, which may provide a basis for developing new differentiation therapies for APL.
Journal
|
ITGAM (Integrin, alpha M) • ITGAX (Integrin Subunit Alpha X)
16d
Case report: TTMV::RARA-positive pediatric APL with spinal cord compression as initial presentation: unique clinical features and therapeutic outcomes revealed by a 12-case systematic cohort analysis. (PubMed, Front Oncol)
While limited by a single-case observation and heterogeneous reported data that preclude statistical analysis, this report expands the recognized clinical spectrum of TTMV::RARA APL and documents three previously unreported observations: spinal cord compression as the initial presentation, venetoclax-induced remission, and oral arsenic compound utilization. These findings suggest RNA-based fusion testing may be informative for PML::RARA-negative suspected APL with atypical presentations, although optimal diagnostic and therapeutic approaches await validation through collaborative studies.
Journal
|
CD33 (CD33 Molecule) • CD34 (CD34 molecule)
|
Venclexta (venetoclax)
16d
Realgar Transforming Solution suppresses KG-1a-derived CD34+CD38- acute myeloid leukemia stem cell-like phenotypes in association with ER-mitochondrial stress and mitophagy-related alterations. (PubMed, J Ethnopharmacol)
RTS suppressed stemness-associated phenotypic features in a KG-1a-derived CD34+CD38- LSC-like model. These effects were associated with ERS, mitochondrial injury, and PINK1/Parkin-related mitophagy-like alterations.
Journal • IO biomarker
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD34 (CD34 molecule) • ATF4 (Activating Transcription Factor 4)
20d
Acute promyelocytic leukemia with secondary myelofibrosis and positive CD34 expression. (PubMed, Int J Clin Exp Pathol)
Furthermore, marked myelofibrosis was identified in our patient - an unusual finding for APL. By sharing this observation, we emphasize the importance of a comprehensive approach in achieving an accurate and timely diagnosis of APL, including the integration of morphologic assessment, immunohistochemistry, flow cytometry, and molecular techniques.
Journal
|
RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia) • CD34 (CD34 molecule)
|
Chr t(15;17)
21d
Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients (clinicaltrials.gov)
P2/3, N=60, Not yet recruiting, The Affiliated People's Hospital of Ningbo University
New P2/3 trial
|
Jakafi (ruxolitinib) • lisaftoclax (APG-2575)
22d
Advancing in Acute Promyelocytic Leukemia Therapy Research: The Role of 3-Alkylpyridine Alkaloid Analogs in Overcoming Genetic and Molecular Barriers. (PubMed, Anticancer Agents Med Chem)
This study highlights the potential of 3-APA analogs as effective cytotoxic agents in the treatment of APL. The compounds demonstrated significant apoptotic activity and altered gene expression, particularly in apoptosis regulation and oxidative stress pathways. These findings suggest that 3-APA analogs may serve as valuable candidates for future therapeutic development in APL treatment, warranting further research into their molecular mechanisms and clinical applicability.
Journal • PARP Biomarker • IO biomarker
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • BCL2 (B-cell CLL/lymphoma 2) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
22d
Targeting ZMIZ1 induces differentiation in acute myeloid leukemia via chromatin remodeling. (PubMed, Signal Transduct Target Ther)
Finally, we report the development of small-compounds potentially targeting ZMIZ1 with high binding affinity, selective on-target activity, and potent in vivo efficacy in both the murine AML model and AML organoids. Collectively, these findings uncover ZMIZ1 as a targetable epigenetic vulnerability in AML, underscoring its potential as a promising therapeutic target for differentiation-based treatment strategies.
Journal
|
MEF2D (Myocyte Enhancer Factor 2D)
24d
Isotretinoin Use During Consolidation in Acute Promyelocytic Leukemia Following Standard All-Trans Retinoic Acid (ATRA)-Based Induction: A Case Report. (PubMed, Cureus)
The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has significantly improved outcomes in patients with APL. The patient achieved molecular complete remission within two months of initiating isotretinoin-based consolidation therapy and continues to have negative PML::RARA reverse transcriptase polymerase chain reaction (RT-PCR) results, with sustained remission at 18 months of follow-up with ongoing molecular monitoring every three months. Although the concurrent use of ATO and prior ATRA-based induction are important confounders, this case highlights the potential role of isotretinoin as a cost-effective alternative retinoid for consolidation therapy in APL when ATRA is inaccessible, although ATRA remains the recommended standard treatment.
Journal
|
RARA (Retinoic Acid Receptor Alpha)
|
arsenic trioxide
24d
An interface engineered ZnO/rGO/Au NPs@MoS2 heterojunction for enhanced photoelectrochemical DNA sensing. (PubMed, Nanoscale)
Finite-difference time-domain (FDTD) simulations further confirm the contribution of plasmonic enhancement to the improved photoelectric response. This work presents a robust strategy for constructing advanced heterojunction photoelectrodes and provides a promising PEC platform for ultrasensitive biomarker detection in bioanalysis and clinical diagnostics.
Journal
|
PML (Promyelocytic Leukemia)
|
PML-RARA fusion
24d
Immunophenotypic aberrancies in molecularly confirmed acute promyelocytic leukemia: lessons from two cases. (PubMed, J Hematop)
APL may exhibit immunophenotypic aberrancies mimicking MPAL. Molecular confirmation of PML::RARA and an integrated diagnostic approach are essential to avoid misclassification and ensure timely therapy.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • CD19 (CD19 Molecule) • CD34 (CD34 molecule) • CD14 (CD14 Molecule) • CD7 (CD7 Molecule)
|
FLT3-ITD mutation • Chr t(15;17)